Clinical Trials
The Department of Psychiatry & Behavioral Sciences invites research subjects to participate in studies aimed at improving the diagnosis and treatment of schizophrenia, psychosis (e.g., hearing voices, paranoia), bipolar disorder, depression, and anxiety.
Our clinical trial team consists of skilled psychiatrists and research coordinators who will carefully monitor subjects during their participation. Browse the active studies below or call our Clinical Research Program office at 312-503-7071.
Feinberg Clinical Trials
Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search for trials by disease or condition.
| Trials |
|---|
Northwestern University The Department of Psychiatry and Behavioral Sciences, Clinical Research Program (NU CRP) Recruitment PipelineThe recruitment pipeline provides research staff with an organized system of identifying researchsubjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed with certain neurological diseases such as Alzheimer’… The recruitment pipeline provides research staff with an organized system of identifying researchsubjects.NU CRP clinical research studies covers a wide spectrum of Axis I Diagnoses such as schizophrenia, depression, anxiety, etc. NU CRP also conducts research studies for patients who are diagnosed with certain neurological diseases such as Alzheimer’s disease, Tourette’s Syndrome, etc. NU CRP conducts basic, translational and clinical research. Personal Health Information (PHI) will not be collected. All information collected in this recruitmentregistry is based on the patient self-report. You will be contacted to answer additional questions by someone in the study staff and to determine your eligibility for the current studies. Copy Study URL to Clipboard Copy |
The EMPOWER Study: A new drug treatment for schizophreniaWhat is this study about?The purpose of this trial is to study a new medication emraclidine to treat symptoms of schizophrenia in adults. This medication works in a different, novel way compared to traditional antipsychotics. The study may be a good fit for individuals who either do not tolerate … What is this study about? The purpose of this trial is to study a new medication emraclidine to treat symptoms of schizophrenia in adults. This medication works in a different, novel way compared to traditional antipsychotics. The study may be a good fit for individuals who either do not tolerate or benefit from currently available treatments. ALL participants received active treatment (no one receives placebo or sugar pill). What will I do if I decide to participate? Participants will attend 23 study visits over the course of 1 year in person at Northwestern Hospital where they will undergo various clinical assessments and answer questions regarding mental health symptoms. The first two visits are for screening purposes to determine eligibility. Participants will take the study medication for 52 weeks. Copy Study URL to Clipboard Copy |
The CLICK Study- a digital mental health app for adults with schizophreniaWhat is this study about? The purpose of this study is to evaluate a digital mental health application for adults with schizophrenia who are experiencing social withdrawal, reduced emotions and decreased motivation. This application will be added to the current antipsychotic therapy treatment.What will I do if I participate? … What is this study about? The purpose of this study is to evaluate a digital mental health application for adults with schizophrenia who are experiencing social withdrawal, reduced emotions and decreased motivation. This application will be added to the current antipsychotic therapy treatment. What will I do if I participate? Participants will take part in 4 study visits in-person at Northwestern Hospital and 3 remote visits over the course of 4 months. Visits will include clinical assessments and questionnaires regarding mental health symptoms. In addition, participants will use the digital application daily for 5-30 minutes. Copy Study URL to Clipboard Copy |
Karuna ARISE StudyThis study is examining a new medication KarXT (muscarinic receptor modulator) that will be added to the current medications. The aim is to treat partially remitted psychosis in schizophrenia. Participants will have the opportunity to continue in follow up study for the study medication. What will I do if I … This study is examining a new medication KarXT (muscarinic receptor modulator) that will be added to the current medications. The aim is to treat partially remitted psychosis in schizophrenia. Participants will have the opportunity to continue in follow up study for the study medication.
What will I do if I participate? Participants will attend 9 study visits over the course of 11 weeks in person, will undergo various clinical assessments and answer questions regarding mental health symptoms. The first two visits are for screening purposes to determine eligibility. Participants will take the study medication for 6 weeks in addition to their current medication. Copy Study URL to Clipboard Copy |
REL-1017 for Major Depressive Disorder (The RELIANCE-II Study)The Relmada Study is evaluating a new medication Esmethadone to treat depression. This study is for patients diagnosed with depression lasting more than 2 months and whose symptoms are not adequately controlled with current antidepressant therapy. This study medication is an add on treatment for depression .The main goal of … The Relmada Study is evaluating a new medication Esmethadone to treat depression. This study is for patients diagnosed with depression lasting more than 2 months and whose symptoms are not adequately controlled with current antidepressant therapy. This study medication is an add on treatment for depression .The main goal of this study is to learn how safe the study drug is and how well the study drug works when taken with the antidepressants you are currently taking for depression. Eligibility Criteria Diagnosed with Major Depressive disorder, currently experiencing an episode of depression lasting 8 weeks to 36 months Must be stable on anti-depressants for 6 weeks, with inadequate improvement. Copy Study URL to Clipboard Copy |